arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cartesian Therapeutics, Inc.

RNAC
$7.84 ▼ -0.26 (-3.27%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
41 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Cartesian Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $231.0M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC 31.8%
FCF / Share $-0.72
Trailing P/E 16.7x
Price / Book
FCF Yield
Debt / Equity -0.42
info Valuation on last close. End-of-day price, Sep 23, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-39.18M
↓ -121.2%
Operating Margin Operating profit as % of sales
41.1%
↑ +118.0%
FCF / Share Free cash flow per share
$-0.72
↑ +12.2%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 41 quarters